1. Home
  2. LOB vs MESO Comparison

LOB vs MESO Comparison

Compare LOB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Live Oak Bancshares Inc.

LOB

Live Oak Bancshares Inc.

HOLD

Current Price

$39.48

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.43

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOB
MESO
Founded
2008
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
LOB
MESO
Price
$39.48
$16.43
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$43.00
N/A
AVG Volume (30 Days)
168.1K
180.2K
Earning Date
04-22-2026
02-26-2026
Dividend Yield
0.32%
N/A
EPS Growth
31.95
N/A
EPS
1.35
N/A
Revenue
N/A
N/A
Revenue This Year
$35.52
$629.74
Revenue Next Year
$16.03
$30.65
P/E Ratio
$29.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.36
$13.05
52 Week High
$44.53
$21.50

Technical Indicators

Market Signals
Indicator
LOB
MESO
Relative Strength Index (RSI) 38.99 48.95
Support Level $35.70 $15.37
Resistance Level $42.56 $17.10
Average True Range (ATR) 0.95 0.44
MACD -0.14 -0.09
Stochastic Oscillator 19.60 1.06

Price Performance

Historical Comparison
LOB
MESO

About LOB Live Oak Bancshares Inc.

Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: